Insinga RP - Search Results

1

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators. Insinga RP, et al. Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1585-94. doi: 10.1158/1055-9965.EPI-09-1235. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20530494

2

Model for assessing human papillomavirus vaccination strategies.

Elbasha EH, Dasbach EJ, Insinga RP. Elbasha EH, et al. Among authors: insinga rp. Emerg Infect Dis. 2007 Jan;13(1):28-41. doi: 10.3201/eid1301.060438. Emerg Infect Dis. 2007. PMID: 17370513 Free PMC article.

3

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.

Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Insinga RP, et al. Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):709-15. doi: 10.1158/1055-9965.EPI-06-0846. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17416761 Clinical Trial.

4

Structural differences among cost-effectiveness models of human papillomavirus vaccines.

Insinga RP, Dasbach EJ, Elbasha EH. Insinga RP, et al. Expert Rev Vaccines. 2008 Sep;7(7):895-913. doi: 10.1586/14760584.7.7.895. Expert Rev Vaccines. 2008. PMID: 18767941

5

Human papillomavirus infections and vulvar disease development.

Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA. Garland SM, et al. Among authors: insinga rp. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1777-84. doi: 10.1158/1055-9965.EPI-09-0067. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19505910 Clinical Trial.

6

Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Insinga RP, Dasbach EJ, Elbasha EH. Insinga RP, et al. BMC Infect Dis. 2009 Jul 29;9:119. doi: 10.1186/1471-2334-9-119. BMC Infect Dis. 2009. PMID: 19640281 Free PMC article. Review.

7

Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M, Brown DR, Elbasha E, Muñoz N, Paavonen J, Haupt RM; FUTURE I Investigators. Insinga RP, et al. Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287-96. doi: 10.1158/1055-9965.EPI-10-0791. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21300618 Clinical Trial.

8

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

Dasbach EJ, Insinga RP, Elbasha EH. Dasbach EJ, et al. Among authors: insinga rp. BJOG. 2008 Jul;115(8):947-56. doi: 10.1111/j.1471-0528.2008.01743.x. Epub 2008 May 22. BJOG. 2008. PMID: 18503574

9

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Insinga RP, Dasbach EJ, Elbasha EH. Insinga RP, et al. Pharmacoeconomics. 2005;23(11):1107-22. doi: 10.2165/00019053-200523110-00004. Pharmacoeconomics. 2005. PMID: 16277547 Review.

10

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.

Dasbach EJ, Elbasha EH, Insinga RP. Dasbach EJ, et al. Among authors: insinga rp. Epidemiol Rev. 2006;28:88-100. doi: 10.1093/epirev/mxj006. Epub 2006 Jun 1. Epidemiol Rev. 2006. PMID: 16740585 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page